Evidence map›Paper›PMID 37932470›Full record

ArticleLab animal2023

Aotus nancymaae model predicts human immune response to the placental malaria vaccine candidate VAR2CSA.

Justin Doritchamou, Morten A Nielsen, Arnaud Chêne, Nicola K Viebig, Lynn E Lambert, Adam F Sander, Jean-Philippe Semblat, Sophia Hundt, Sachy Orr-Gonzalez, Christoph Mikkel Janitzek and 25 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lab animal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Current approaches to malaria vaccines.Current opinion in microbiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 6 institutions in 4 countries.

Justin DoritchamouLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-4589-7216
Morten A NielsenCentre for Medical Parasitology at the Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Arnaud ChêneUniversité Paris Cité and Université des Antilles, INSERM, BIGR, Paris, France.
Nicola K ViebigEuropean Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.
Lynn E LambertLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Adam F SanderCentre for Medical Parasitology at the Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Jean-Philippe SemblatUniversité Paris Cité and Université des Antilles, INSERM, BIGR, Paris, France.
Sophia HundtEuropean Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.
Sachy Orr-GonzalezLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Christoph Mikkel JanitzekCentre for Medical Parasitology at the Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Alicia J SpiegelLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Stine B ClemmensenExpreS2ion Biotechnologies, Hørsholm, Denmark.
Marvin L ThomasDivision of Veterinary Resources, Office of Research Services, National Institutes of Health, Bethesda, MD, USA.
Martha C NasonBiostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Maryonne Snow-SmithLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Emma K BarnafoLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Joseph ShiloachBiotechnology Unit, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA.
Beth B ChenLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Steven NadakalLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Kendrick HighsmithLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Tarik OuahesLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Solomon ContehLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Ankur SharmaLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Holly ToranoLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Brandi ButlerLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0003-2606-4064
Karine ReiterLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Kelly M RauschLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Puthupparampil V ScariaLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Charles AndersonLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
David L NarumLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Ali SalantiCentre for Medical Parasitology at the Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Michal FriedLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Thor G TheanderCentre for Medical Parasitology at the Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Benoit GamainUniversité Paris Cité and Université des Antilles, INSERM, BIGR, Paris, France.
Patrick E DuffyLaboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. patrick.duffy@nih.gov.ORCID 0000-0002-4483-5005
National Institutes of Health · USUniversity of Copenhagen · DKInserm · FRHeidelberg University · DEExpreS2ion Biotechnologies (Denmark) · DKNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

Agence Nationale de la Recherche (French National Research Agency) ANR-11-IDEX-0005-02Agence Nationale de la Recherche (French National Research Agency) ANR-16-CE11-0014-01Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation) 42387 and OPP1055855Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research) 202060457
6 · The paper itself

Abstract

Placental malaria vaccines (PMVs) are being developed to prevent severe sequelae of placental malaria (PM) in pregnant women and their offspring. The leading candidate vaccine antigen VAR2CSA mediates parasite binding to placental receptor chondroitin sulfate A (CSA). Despite promising results in small animal studies, recent human trials of the first two PMV candidates (PAMVAC and PRIMVAC) generated limited cross-reactivity and cross-inhibitory activity to heterologous parasites. Here we immunized Aotus nancymaae monkeys with three PMV candidates (PAMVAC, PRIMVAC and ID1-ID2a_M1010) adjuvanted with Alhydrogel, and exploited the model to investigate boosting of functional vaccine responses during PM episodes as well as with nanoparticle antigens. PMV candidates induced high levels of antigen-specific IgG with significant cross-reactivity across PMV antigens by enzyme-linked immunosorbent assay. Conversely, PMV antibodies recognized native VAR2CSA and blocked CSA adhesion of only homologous parasites and not of heterologous parasites. PM episodes did not significantly boost VAR2CSA antibody levels or serum functional activity; nanoparticle and monomer antigens alike boosted serum reactivity but not functional activities. Overall, PMV candidates induced functional antibodies with limited heterologous activity in Aotus monkeys, similar to responses reported in humans. The Aotus model appears suitable for preclinical downselection of PMV candidates and assessment of antibody boosting by PM episodes.

Indexed as

MalariaMalaria, FalciparumMalaria VaccinesAnimalsAntibodies, ProtozoanAntigens, ProtozoanAotidaeFemaleHumansImmunityPlacentaPlasmodium falciparumPregnancyAntibodies, ProtozoanAntigens, ProtozoanMalaria Vaccines

Identifiers

PMID37932470
PMCPMC10689237
OpenAlexW4388409536

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.